MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
- Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1
- First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic pre-conditioning
- AgenT-797 advancing in a randomized phase 2 trial in 2L gastric cancer
"These findings underscore the unique benefits of allogeneic unmodified iNKT cells, including their ability to amplify and accelerate immune response, promote tumor infiltration, and persist without toxic pre-conditioning in heavily pre-treated solid tumor cancers,” said Dr.
Single administration of agenT-797 alone or in combination with anti-PD-1 delivered clinical benefit in heavily pre-treated patients with solid tumors.
- Phase 1 trial of agenT-797 alone or in combination with pembrolizumab or nivolumab without lymphodepletion (n=34) showed durable clinical benefit, including:
- Clinical response in MSI-high 3L gastric cancer patient after failure on pembrolizumab and nivolumab/FOLFOX.
- o Long-term disease stabilization (n=10), including in testicular cancer (SD > 10 months) and anti-PD-1 relapsed/refractory non-small-cell lung cancer (SD > 8 months).
- Tolerable safety profile with no dose-limiting toxicities and no grade >3 neurotoxicity or cytokine release syndrome.
AgenT-797 showed long-term persistence and induced a potent anti-tumor response, including increased infiltration of cytotoxic immune cells into tumors.
- AgenT-797 was detected in the periphery for up to 6 months and persistence was independent of HLA matching.
- An increased level of immune cell tumor infiltration and neoantigen driven expansion of anti-tumor cytotoxic T cells was observed following administration.
- AgenT-797 promoted a systemic and local pro-inflammatory cytokine signature.
Expansion of clinical programs are underway in additional solid tumor settings, including relapsed/refractory gastric cancer.
- Expected launch of a randomized phase 2 trial in 2L gastric cancer, led by Dr.
Yelena Janjigian, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, by year-end 2023. The study will evaluate agenT-797 in combination with standard of care chemotherapy +/- Agenus’ botensilimab/balstilimab combination.
- Expansion of phase 1 study underway to evaluate further signals in select tumor types, including non-small cell lung cancer and testicular cancer, and evaluate multi-dosing of agenT-797.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797 alone and in combination with anti-PD-1, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the
Source: MiNK Therapeutics